Skip to main content

Trending Discover PulsePenny Commodities

Home
Trending Tickers

US Markets Closed

AI-assisted · Not financial adviceNot advice

© 2026 Ranjesh Chitharanjan

Trending Discover Pulse

Explore

High-volatility small caps

Gold, oil, agriculture & metals

Home
Trending Tickers
$EDIT

US Markets Closed

AI-assisted · Not financial adviceNot advice

AI-assisted · Not financial advice.

$EDIT - Editas Medicine | MarketMind | MarketMind

$EDIT

Editas Medicine· 4/3/2026, 6:35:44 PM

Data Checks· 0 of 1 passed

Insiders (90d)

0 buys, 3 sells

Last: SELL Mar 3· 31d ago

▼Net selling $13K

Reddit: Optimistic · AlignedAttention: Watching

Community Take (7D)

Skepticism in retail about market timing contrasts with news of regulatory progress. This divergence suggests that while investors are cautious, the company is making strides.

News vs Reddit

Aligned Bullish

News Signal

News Outlets · Analyst Coverage

bullish

Signal Quality50%

Reddit Sentiment

Reddit · Community Discussion

bullish

Confidence Level40%

The Story

|

News Summary

EDIT-401 on track for IND submission

Key Events

Mar 9, 2001:Lead candidate, EDIT-401, demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026.

Sentiment: 70% bullish / 30% neutral (early) → 80% bullish / 20% neutral (late)

Impact: The discussion evolved from focusing on preclinical success to highlighting the upcoming IND submission and clinical trial plans, indicating strong confidence in future developments.

Analyst ConsensusBuy (25 analysts)

Target: $6 avg

14 Buy · 9 Hold · 2 Sell

Signal

Bullish

Confidence

50%

Based on curated news sources (not retail comments)

Over the last 7 days: Strong preclinical results and upcoming clinical trials indicate a highly positive outlook for Editas Medicine.

SentimentEuphoria

AnalysisHype

Bullish Factors

✓Lead candidate, EDIT-401, demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 [FMP|Mar 09]
✓Preparing to initiate Company's first-in-human clinical trial in HeFH patients, with early human proof-of-concept data on track for year-end 2026 [FMP|Mar 09]

Risk Factors

No bear risks identified

Analyze with AI yahoo!finance Reddit Answers